PT  - JOURNAL ARTICLE
AU  - Wynne, Chris
AU  - Hamilton, Paul
AU  - Li, Jingxin
AU  - Mo, Chen
AU  - Yu, Jiaping
AU  - Yao, Wenrong
AU  - Yue, Zijing
AU  - Zhang, Xi
AU  - Zhang, Jianhui
AU  - Hong, Kunxue
AU  - Chen, Jianping
AU  - Liu, Yong
AU  - Zhu, Fengcai
TI  - The preliminary safety and immunogenicity results of a randomized, double-blind, placebo-controlled Phase I trial for a recombinant two-component subunit SARS-CoV-2 vaccine ReCOV
AID  - 10.1101/2022.05.11.22274932
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.05.11.22274932
4099  - http://medrxiv.org/content/early/2022/05/14/2022.05.11.22274932.short
4100  - http://medrxiv.org/content/early/2022/05/14/2022.05.11.22274932.full
AB  - Background The ReCOV is a recombinant trimeric two-component SARS-CoV-2 subunit vaccine adjuvanted with BFA03. We report the preliminary safety and immunogenicity results for the ReCOV.Methods This first in human, randomized, double-blind, placebo-controlled phase I study, was conducted at 2 study sites in New Zealand. Subjects were stratified into two age cohorts (18-55 years and 56-80 years old) and then randomly assigned in a 4:1 ratio to receive two 0.5 mL intramuscular doses of the ReCOV vaccine (20µg or 40µg, adjuvanted with BFA03 in each) or placebo, 21 days apart. The primary endpoints were incidence of solicited local and systemic adverse events (AEs) and unsolicited AEs after each dose; incidence of serious adverse events (SAEs) up to 30 days after the second dose; changes in clinical laboratory tests from baseline up to 7 days after each dose; and changes in vital signs from baseline up to 30 days after the second dose. The key secondary endpoints for immunogenicity were neutralizing antibody titers against SARS-CoV-2, S1 receptor binding domain (RBD) and N-terminal domain (NTD) IgG titers post-vaccination. The T cell-specific immune response elicited by ReCOV were also evaluated. The trial was registered with ClinicalTrials.gov (NCT04818801).Findings One hundred participants (50 for each age group) were randomized. The incidence of solicited local AEs in 20μg ReCOV, 40μg ReCOV, and pooled placebo group among younger adults were 60.0%, 70.0%, and 10.0%, respectively, while among older adults were 55.0%, 84.2%, and 10.0%, respectively. The incidence of solicited systemic AEs in 20μg ReCOV, 40μg ReCOV, and pooled placebo group among younger adults were 60.0%, 60.0%, and 30.0%, respectively, while among older adults were 50.0%, 52.6%, and 50.0%, respectively. All solicited AEs and unsolicited AEs were mild. No vaccination-related SAE, adverse events of special interest, and AE leading to early discontinuation were reported.ReCOV elicited SARS-CoV-2 neutralizing antibody after the first vaccination, which were increased further after the second vaccination irrespective of dose and age groups. The neutralizing antibody against wild-type SARS-CoV-2 peaked at 14 days post the second vaccination in both 20µg and 40µg ReCOV groups, with GMT of 1643.17 IU/mL and 1289.21 IU/mL among younger adults, and 1122.32 IU/mL and 680.31 IU/mL among older adults, respectively. Similarly, both anti-RBD and anti-NTD specific IgG were elicited after the first vaccination, and peaked at 14 days after the second vaccination. T helper 1 biased cellular responses were observed after ReCOV vaccinations.Interpretation Both 20 and 40µg ReCOV showed good safety profiles and elicited strong immune responses in the younger and the older adults. The results of this study support the accelerated development of ReCOV.Funding Jiangsu Recbio Technology Co., Ltd.Competing Interest StatementChen Mo, Xi Zhang, Jiaping Yu, Wenrong Yao, Zijing Yue, Kunxue Hong, Jianping Chen, Jianhui Zhang, Yong Liu are employees of Jiangsu Recbio Technology Co., Ltd. All the other authors declare no competing interests.Clinical TrialNCT04818801Funding StatementThis work was funded by Jiangsu Recbio Technology Co., Ltd.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Northern B Health and Disability Ethics Committee gave ethical approval for this work. Ethics ref: 21/NTB/108. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors